Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Atezolizumab added to chemotherapy prolongs progression free survival in bladder cancer

ESMO 2019

27 Sep - 1 Oct 2019

Published: 30 Sep 2019

Views: 1221

Rating:

Save

Dr Enrique Grande - Hospital MD Anderson Cancer Center Madrid, Madrid, Spain

Dr Enrique Grande presents data from the IMvigor130 trial during a press conference at the 2019 ESMO congress.

This was a trial evaluating first-line immunotherapy and chemotherapy instead of chemotherapy alone in patients with metastatic urothelial cancer.

Watch Dr Enrique Grande's interview with ecancer here.

Watch Dr Ignacio Duran's comment here.

Read more about the study here.

Related Videos

ESMO 2024: Latest updates in mRCC

Dr Javier Puente, Dr Guillermo De Velasco, Dr Cristina Suárez and Prof Stéphane...

ESMO 2024: Latest updates in mRCC ( Dr Javier Puente, Dr Guillermo De Velasco, Dr Cristina Suárez and Prof Stéphane Oudard )

ESMO 2024: Optimising the personalisation of prostate cancer treatment

Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof...

ESMO 2024: Optimising the personalisation of prostate cancer treatment ( Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg )

ASCO 2024: Lung cancer highlights

Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas...

ASCO 2024: Lung cancer highlights ( Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas Girard and Dr Anna Minchom )

ASCO 2024: Lung cancer roundup

Dr Luis Raez - Memorial Cancer Institute, Miami, USA

ASCO 2024: Lung cancer roundup ( Dr Luis Raez - Memorial Cancer Institute, Miami, USA )

Adjuvant avelumab versus control does not significantly improve DFS but does...

Prof Pier Conte - University of Padova, Padova, Italy

Adjuvant avelumab versus control does not significantly improve DFS but does improve OS in high-risk TNBC patients ( Prof Pier Conte - University of Padova, Padova, Italy )

EAU 2024: Bladder cancer latest

Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Yohann Loriot, Prof Andrea...

EAU 2024: Bladder cancer latest ( Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Yohann Loriot, Prof Andrea Necchi and Dr Cosimo De Nunzio )

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus

Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale...

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus ( Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini )

OncoAlert round up July 28th to August 3rd, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert round up July 28th to August 3rd, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

mRCC: Atezolizumab after progression with prior ICI treatment shows no benefit...

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

mRCC: Atezolizumab after progression with prior ICI treatment shows no benefit and increases toxicity ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )

More from ecancer